Evidence map›Paper›PMID 36918099›Full record

ReviewMolecular & cellular proteomics : MCP2023

Ten Years of Extracellular Matrix Proteomics: Accomplishments, Challenges, and Future Perspectives.

Alexandra Naba

Open access · goldAbstract readReview
In one paragraph

Review in Molecular & cellular proteomics : MCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Type VIII collagen: advances in matrix biology and translational promise.Frontiers in bioengineering and biotechnology · 2025
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Collagen remodeling in breast cancer progression: from molecular mechanisms to diagnostic and therapeutic opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  7. Glycocalyx and basal lamina in neurological disorders.Matrix biology : journal of the International Society for Matrix Biology · 2026
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Assay for Neurocan-Degrading Activity of ADAMTS-12 Metalloprotease.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Alexandra NabaDepartment of Physiology and Biophysics, University of Illinois at Chicago, Chicago, Illinois, USA; University of Illinois Cancer Center, Chicago, Illinois, USA. Electronic address: anaba@uic.edu.
University of Illinois Chicago · US

Funding

Thinking outside the cell: Leveraging HuBMAP data to build the human ECM atlasU01HG012680 · NHGRI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GAO, YU, NABA, ALEXANDRA · 2022 to 2025
$2.0M
Enhanced mass-spectrometry-based approaches for in-depth profiling of the cancer extracellular matrixR21CA261642 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GAO, YU, NABA, ALEXANDRA · 2022 to 2024
$553k
NCI NIH HHS R21 CA261642NHGRI NIH HHS U01 HG012680
6 · The paper itself

Abstract

The extracellular matrix (ECM) is a complex assembly of hundreds of proteins forming the architectural scaffold of multicellular organisms. In addition to its structural role, the ECM conveys signals orchestrating cellular phenotypes. Alterations of ECM composition, abundance, structure, or mechanics have been linked to diseases and disorders affecting all physiological systems, including fibrosis and cancer. Deciphering the protein composition of the ECM and how it changes in pathophysiological contexts is thus the first step toward understanding the roles of the ECM in health and disease and toward the development of therapeutic strategies to correct disease-causing ECM alterations. Potentially, the ECM also represents a vast, yet untapped reservoir of disease biomarkers. ECM proteins are characterized by unique biochemical properties that have hindered their study: they are large, heavily and uniquely posttranslationally modified, and highly insoluble. Overcoming these challenges, we and others have devised mass-spectrometry-based proteomic approaches to define the ECM composition, or "matrisome," of tissues. This first part of this review provides a historical overview of ECM proteomics research and presents the latest advances that now allow the profiling of the ECM of healthy and diseased tissues. The second part highlights recent examples illustrating how ECM proteomics has emerged as a powerful discovery pipeline to identify prognostic cancer biomarkers. The third part discusses remaining challenges limiting our ability to translate findings to clinical application and proposes approaches to overcome them. Lastly, the review introduces readers to resources available to facilitate the interpretation of ECM proteomics datasets. The ECM was once thought to be impenetrable. Mass spectrometry-based proteomics has proven to be a powerful tool to decode the ECM. In light of the progress made over the past decade, there are reasons to believe that the in-depth exploration of the matrisome is within reach and that we may soon witness the first translational application of ECM proteomics.

Indexed as

NeoplasmsProteomicsBiomarkers, TumorExtracellular MatrixExtracellular Matrix ProteinsHumansBiomarkers, TumorExtracellular Matrix Proteinsbiomarkersmatrisomemicroenvironmentposttranslational modificationsprotein solubility

Identifiers

PMID36918099
PMCPMC10152135
OpenAlexW4323980941

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.